chemed corp. - CHE

CHE

Close Chg Chg %
520.26 -7.16 -1.38%

Closed Market

513.10

-7.16 (1.38%)

Volume: 156.99K

Last Updated:

Oct 23, 2026, 3:59 PM EDT

Company Overview: chemed corp. - CHE

CHE Key Data

Open

$520.14

Day Range

510.99 - 520.95

52 Week Range

365.25 - 553.74

Market Cap

$6.68B

Shares Outstanding

13.07M

Public Float

12.82M

Beta

0.51

Rev. Per Employee

N/A

P/E Ratio

25.69

EPS

$19.93

Yield

48.06%

Dividend

$0.70

EX-DIVIDEND DATE

Aug 17, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

141.68K

 

CHE Performance

1 Week
 
0.12%
 
1 Month
 
0.16%
 
3 Months
 
0.36%
 
1 Year
 
17.49%
 
5 Years
 
13.84%
 

CHE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About chemed corp. - CHE

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

CHE At a Glance

Chemed Corp.
255 East 5th Street
Cincinnati, Ohio 45202-4726
Phone 1-513-762-6690 Revenue 2.53B
Industry Hospital/Nursing Management Net Income 265.24M
Sector Health Services 2025 Sales Growth 4.059%
Fiscal Year-end 12 / 2026 Employees 15,811
View SEC Filings

CHE Valuation

P/E Current 25.685
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 23.326
Price to Sales Ratio 2.445
Price to Book Ratio 5.99
Price to Cash Flow Ratio 15.93
Enterprise Value to EBITDA 15.436
Enterprise Value to Sales 2.477
Total Debt to Enterprise Value 0.025

CHE Efficiency

Revenue/Employee 160,013.788
Income Per Employee 16,775.536
Receivables Turnover 13.857
Total Asset Turnover 1.485

CHE Liquidity

Current Ratio 1.054
Quick Ratio 1.028
Cash Ratio 0.26

CHE Profitability

Gross Margin 29.974
Operating Margin 13.485
Pretax Margin 14.062
Net Margin 10.484
Return on Assets 15.568
Return on Equity 25.28
Return on Total Capital 23.386
Return on Invested Capital 23.066

CHE Capital Structure

Total Debt to Total Equity 15.801
Total Debt to Total Capital 13.645
Total Debt to Total Assets 9.436
Long-Term Debt to Equity 10.503
Long-Term Debt to Total Capital 9.07
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Chemed Corp. - CHE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.13B 2.26B 2.43B 2.53B
Sales Growth
-0.20% +6.06% +7.37% +4.06%
Cost of Goods Sold (COGS) incl D&A
1.43B 1.53B 1.64B 1.77B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
59.17M 60.87M 63.05M 64.84M
Depreciation
49.10M 50.80M 52.86M 54.56M
Amortization of Intangibles
10.07M 10.06M 10.19M 10.28M
COGS Growth
+0.04% +6.82% +7.44% +8.03%
Gross Income
705.91M 737.95M 791.30M 758.34M
Gross Income Growth
-0.68% +4.54% +7.23% -4.16%
Gross Profit Margin
+33.06% +32.59% +32.55% +29.97%
2022 2023 2024 2025 5-year trend
SG&A Expense
358.73M 395.12M 417.89M 417.19M
Research & Development
- - - -
-
Other SG&A
358.73M 395.12M 417.89M 417.19M
SGA Growth
-2.67% +10.15% +5.76% -0.17%
Other Operating Expense
- - - 446.00K
-
Unusual Expense
2.61M 2.05M 6.47M 3.07M
EBIT after Unusual Expense
344.57M 340.78M 366.49M 338.08M
Non Operating Income/Expense
(10.31M) 12.70M 34.75M 19.44M
Non-Operating Interest Income
355.00K 6.27M 14.61M 8.74M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.58M 3.11M 1.78M 1.75M
Interest Expense Growth
+145.40% -32.20% -42.73% -1.69%
Gross Interest Expense
4.58M 3.11M 1.78M 1.75M
Interest Capitalized
- - - -
-
Pretax Income
329.68M 350.37M 399.46M 355.78M
Pretax Income Growth
-5.89% +6.28% +14.01% -10.94%
Pretax Margin
+15.44% +15.47% +16.43% +14.06%
Income Tax
80.06M 77.86M 97.47M 90.54M
Income Tax - Current - Domestic
64.72M 85.32M 101.10M 96.08M
Income Tax - Current - Foreign
505.00K 569.00K 501.00K 406.00K
Income Tax - Deferred - Domestic
14.82M (8.03M) (4.14M) (5.94M)
Income Tax - Deferred - Foreign
6.00K 2.00K 2.00K (3.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
249.62M 272.51M 302.00M 265.24M
Minority Interest Expense
- - - -
-
Net Income
249.62M 272.51M 302.00M 265.24M
Net Income Growth
-7.05% +9.17% +10.82% -12.17%
Net Margin Growth
+11.69% +12.03% +12.42% +10.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
249.62M 272.51M 302.00M 265.24M
Preferred Dividends
- - - -
-
Net Income Available to Common
249.62M 272.51M 302.00M 265.24M
EPS (Basic)
16.7207 18.1069 20.1011 18.4219
EPS (Basic) Growth
-2.43% +8.29% +11.01% -8.35%
Basic Shares Outstanding
14.93M 15.05M 15.02M 14.40M
EPS (Diluted)
16.5325 17.9282 19.8867 18.3429
EPS (Diluted) Growth
-1.88% +8.44% +10.92% -7.76%
Diluted Shares Outstanding
15.10M 15.20M 15.19M 14.46M
EBITDA
406.36M 403.69M 436.01M 406.00M
EBITDA Growth
+1.28% -0.66% +8.01% -6.88%
EBITDA Margin
+19.03% +17.83% +17.93% +16.05%

Snapshot

Average Recommendation HOLD Average Target Price 571.60
Number of Ratings 6 Current Quarters Estimate 7.375
FY Report Date 12 / 2026 Current Year's Estimate 25.494
Last Quarter’s Earnings 6.47 Median PE on CY Estimate N/A
Year Ago Earnings 21.55 Next Fiscal Year Estimate 27.518
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 2 5 5
Mean Estimate 7.37 5.85 25.49 27.52
High Estimates 7.55 6.22 25.69 28.42
Low Estimate 7.12 5.47 25.31 26.61
Coefficient of Variance 2.41 9.07 0.58 2.38

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 3 3 4
UNDERWEIGHT 1 1 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Chemed Corp. - CHE

Date Name Shares Transaction Value
Oct 23, 2026 Spencer S. Lee executive vice president 23,222 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 23, 2026 Brian C Judkins VP and Chief Legal Officer 40,673 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 23, 2026 Joel L. Wherley CEO - Vitas Healthcare 42,906 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 1, 2026 Kevin J. McNamara president and CEO; Director 66,418 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $513.45 per share 34,102,322.10
Oct 1, 2026 Spencer S. Lee executive vice president 14,851 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $508.93 per share 7,558,119.43
Oct 1, 2026 Spencer S. Lee executive vice president 16,097 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 4, 2026 Patrick P. Grace Director 3,533 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $532 per share 1,879,556.00
Dec 30, 2025 Andrea R. Lindell Director 5,539 Bona fide gift 0.00

Chemed Corp. in the News